PresentationsNX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases By webmaster / November 16, 2024
PresentationsIRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model By webmaster / November 15, 2024
PresentationsClinical Activity of NX-5948: A First-in-Class BTK Degrader By webmaster / October 30, 2024
PresentationsAn Orally Bioavailable, Brain Penetrant, Pan-Mutant BRAF Degrader for the Treatment of Primary and Inhibitor-Resistant Solid Tumors By webmaster / October 29, 2024
PresentationsNX-5948: BTK Degrader with Activity in Lymphoid Malignancies By webmaster / October 19, 2024
PresentationsScreening DNA Binding Proteins with DNA Encoded Libraries By webmaster / October 3, 2024
PresentationsThe Evolving Chemical Space of Bi-functional Degraders Targeting the CNS By webmaster / October 1, 2024
PresentationsRational Discovery of a Small Molecule Intramolecular Glue Inhibitor of CBL-B that Enhances T-cell Function By webmaster / October 1, 2024
PresentationsAccelerating Targeted Protein Degrader Discovery with Automated and Integrated Direct-To-Biology Screening By webmaster / September 10, 2024
PresentationsTargeted Protein Degraders As Next Generation Antibody Payloads By AldenMC Production / September 9, 2024
